• 목록
• 답변

Arbormed Secures USD 1.6 Million Investment from U.S.-Based OIC… Pre-IPO in Full Swing

Arbormed, a biotechnology company specializing in the development of therapies for rare and intractable diseases (Co-CEOs Kyojin Park and Wonbin Lim), has secured an investment of approximately USD 1.6 million (approximately KRW 2.4 billion) from U.S.-based investor OIC, LLC, thereby launching its Pre-IPO round in earnest.

This investment is particularly meaningful in that it demonstrates that the value of ArborMed’s pipeline and its global growth potential have been recognized in overseas markets. The Company expects that this funding will further accelerate the development of its core pipeline and the expansion of its global business.

OIC, LLC, which participated in the investment, is a subsidiary of U.S.-based OptiSource, LLC. Through this investment, Arbormed plans to broaden the possibility of collaboration with OIC and its parent company OptiSource, and to strengthen strategic partnerships throughout the entire process of product development and commercialization in the global market. The Company’s plan is not limited to simply attracting investment, but also to expand practical points of contact in terms of business development.

This investment was made during ArborMed’s Pre-IPO fundraising process. Based on the secured funds, the Company plans to steadily advance the R&D of major pipeline programs including ARBM-101, while also accelerating preparations for global clinical trials and business expansion. In addition, the Company expects that this will add momentum to its long-term preparations for an initial public offering (IPO).

Arbormed is a biotechnology company that has built its pipeline centered on the development of treatments for rare and intractable diseases. The Company explained that, through the participation of this overseas investor, it has once again confirmed the global market’s interest in its technological competitiveness and business potential. In particular, the Company believes that the expansion of its points of contact with the U.S. investment network will have a positive effect on strengthening the foundation for its future entry into the North American and European markets.

Kyojin Park, Co-CEO of Arbormed, said, “This overseas investment is an achievement that demonstrates that Arbormed’s drug development capabilities and business strategy are competitive even by global standards,” adding, “We will continue to advance the development of our core pipeline without disruption and diligently proceed with our Pre-IPO and IPO preparations.”

Meanwhile, following its recent technology transfer agreement with Belgium-based Hyloris, ArborMed has now continued its momentum with this U.S. investment, broadening its global business development and R&D efforts on both fronts. The Company plans to continue increasing its corporate value through global market expansion and the expansion of partnerships going forward.